Actions of prostaglandins in peripheral vascular beds. 1981

L P Feigen

The prostaglandins comprise a large family of substances that includes primary prostaglandins (PGE2, F2 alpha, D2) prostacyclin (PGI2), and thromboxanes (TxA2, B2), all of which exhibit some vascular activity. The activity of each prostaglandin may be species- and organ-dependent, and the type of prostaglandin produced in a tissue is often dependent on the presence of terminal enzyme systems in that tissue. This paper describes the effects of certain members of the prostaglandin family on the mesenteric and renal vascular beds of anesthetized dogs. In the kidney, arachidonic acid, PGE2, D2, and I2 all produce vasodilation when studied by bolus injection techniques. PGF2 alpha is relatively inactive. In the mesenteric vascular bed arachidonate, PGE2 and PGI2 are vasodilators whereas PGD2 and PGF2 are vasoconstrictors. The direct actions of thromboxanes A2 and the endoperoxide PGH2 are uncertain because of their very short half-lives in plasma. Infusion of prostaglandins E2 and I2 into the left ventricle produces vasodilation in both the kidney and the gut. In the mesenteric vascular bed, however, vasodilation during PGE2 (but not PGI2) infusion is a transient phenomenon and the blood flow returns to control levels within the first few minutes of infusion. The vascular actions of prostaglandins are therefore complex and are dependent not only on organ and species, but on experimental technique as well.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011460 Prostaglandins F (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. PGF
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001095 Arachidonic Acids Eicosatetraenoic Acids,Acids, Arachidonic,Acids, Eicosatetraenoic
D014655 Vascular Resistance The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT. Peripheral Resistance,Total Peripheral Resistance,Pulmonary Vascular Resistance,Systemic Vascular Resistance,Peripheral Resistance, Total,Resistance, Peripheral,Resistance, Pulmonary Vascular,Resistance, Systemic Vascular,Resistance, Total Peripheral,Resistance, Vascular,Vascular Resistance, Pulmonary,Vascular Resistance, Systemic
D014661 Vasoconstriction The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE. Vasoconstrictions

Related Publications

L P Feigen
December 1980, Lancet (London, England),
L P Feigen
January 1953, Bulletin of the Johns Hopkins Hospital,
L P Feigen
November 1995, Journal of cardiovascular pharmacology,
L P Feigen
May 1983, Lancet (London, England),
L P Feigen
November 1961, The American journal of cardiology,
L P Feigen
February 1962, Clinical science,
L P Feigen
October 1974, Japanese journal of pharmacology,
L P Feigen
July 1959, Physiological reviews,
L P Feigen
December 1983, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
L P Feigen
October 1975, British journal of pharmacology,
Copied contents to your clipboard!